 |
|
Antipsychotic Agents and Cardiometabolic Morbidity in Youth—Reply
Roger S. McIntyre, MD, FRCPC;
Jeanette M. Jerrell, PhD
Arch Pediatr Adolesc Med. 2009;163(4):395.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We appreciate the comments from Drs Kruszewski and Paczynski. We share their general concern regarding the cardiometabolic hazards posed by the use of SGAs in young populations. This concern provided the impetus for us to conduct the analysis and present our findings. During the past decade, several SGAs have been introduced, widely disseminated, and highly promoted (perhaps through "aggressive off-label marketing") as treatment options for disparate emotional, cognitive, and behavioral therapeutic targets. It is our view that SGAs provide unequivocal efficacy and, as a class of drugs, are an important adjunct to the armamentarium of treatment options available to practitioners. However, results from pragmatic trials in adult and pediatric populations along with clinical experience have underscored the finding that many, but not all, SGAs are associated with significant metabolic risks. This observation has reduced the early therapeutic euphoria that . . . [Full Text of this Article] AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and Adolescents
Roger S. McIntyre and Jeanette M. Jerrell
Arch Pediatr Adolesc Med. 2008;162(10):929-935.
ABSTRACT
| FULL TEXT
RELATED LETTER
Antipsychotic Agents and Cardiometabolic Morbidity in Youth
Stefan P. Kruszewski and Richard P. Paczynski
Arch Pediatr Adolesc Med. 2009;163(4):394-395.
EXTRACT
| FULL TEXT
|
